In addition, the IL-17A antagonist (secukinumab) used to treat moderate to severe plaque psoriasis can significantly inhibit the secretion of CXCL1 and CXCL8 by keratinocytes, and almost completely eliminate the infiltration of neutrophils in skin lesions (Reich et al., 2015). Here, CXCL1 is linked to psoriasis vulgaris.